HOME Top Market Reports Regenerative Medicines Market by Therapy (Cell Therapy, Gene Therapy, Immunotherapy, Tissue Engineering), Product (Cell-Based, Acellular), Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Cardiovascular, Central Nervous System), Region - Global Forecast to 2021

Regenerative Medicines Market by Therapy (Cell Therapy, Gene Therapy, Immunotherapy, Tissue Engineering), Product (Cell-Based, Acellular), Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Cardiovascular, Central Nervous System), Region - Global Forecast to 2021

By: marketsandmarkets.com
Publishing Date: July 2016
Report Code: BT 4419

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The global regenerative medicines market is expected to reach USD 49.41 Billion by 2021 from USD 17.06 Billion in 2016, at a CAGR of 23.7%. The global market is broadly classified by product, application, therapy, and region.

On the basis of product, market is segmented into cell-based and acellular products. The cell-based products segment is further segmented into allogeneic and autologous products. Cell-based product segment is expected to account for the largest share of the global market in 2016 owing to the increasing demand of cell-based products, rapid rise in FDA approvals in the U.S., increasing organ transplantations, and increasing government initiatives.

On the basis of application, the regenerative medicines market is segmented into orthopaedic & musculoskeletal spine, dermatology, CNS, cardiovascular, oncology, diabetes, and others. The orthopaedic & musculoskeletal spine segment is expected to account for the largest share of this market because of the increasing number of FDA approvals in orthopaedic and increasing focus on research on musculoskeletal spine.

Therapy segments included in the regenerative medicines market are cell therapy, gene therapy, immunotherapy, and tissue engineering. The cell therapy segment is expected to account for the largest share of the global market in 2016. Rising government initiatives, increasing investments by pharmaceutical companies on the research on cell therapies, and launch of various cell therapy products in the market are driving this segment.

Geographically, the market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Growth in the North American segment is primarily driven by increasing demand of regenerative medicines, advancement in research and development, and launch of new products in the market.

Apart from a comprehensive geographic and product analysis along with the market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the market.

The prominent players in the market include Celgene Corporation (U.S.), Acelity (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), among others.

Target Audience for this Report:

  • Healthcare Providers & Clinical Experts
  • Service Providers
  • Therapeutic Companies
  • Insurers
  • Contract Manufacturers
  • Academic Research Institutes

Value Addition for the Buyer:

This report aims to provide insights into the global regenerative medicines market. It provides valuable information on the product applications, and therapy, in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

The above-mentioned information would benefit the buyer by helping them understand the market dynamics. In addition, the forecasts provided in the report will enable firms to understand the trends in this market and better position themselves to capitalize the growth opportunities.

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report:

This report categorizes the regenerative medicines market into the following segments:

Regenerative Medicines Market, By Product

  • Cell-based Products
    • Allogeneic
    • Autologous
  • Scaffold Free

Regenerative Medicines Market, By Therapy

  • Cell Therapy
  • Gene Therapy
  • Immunotherapy
  • Tissue Engineering

Regenerative Medicines Market, By Application

  • Orthopaedic & Musculoskeletal Spine
  • Dermatology
  • CNS
  • Cardiovascular
  • Oncology
  • Diabetes
  • Others

Regenerative Medicines Market, By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Spain
    • RoE
  • Asia-Pacific
  • Rest of the World (RoW)

Customization Options:

  • Company Information: Detailed company profiles of up to five market players
  • Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

Table of Contents

1 Introduction (Page No. - 14)
    1.1 Objectives of the Study
    1.2 Regenerative Medicines Market Definition
    1.3 Regenerative Medicines Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency & Pricing
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 18)
    2.1 Regenerative Medicines Market Size Estimation
    2.2 Regenerative Medicines Market Breakdown and Data Triangulation
    2.3 Regenerative Medicines Market Share Estimation
           2.3.1 Key Data From Secondary Sources
           2.3.2 Key Data From Primary Sources
           2.3.3 Assumptions for the Study

3 Executive Summary (Page No. - 25)

4 Premium Insights (Page No. - 28)
    4.1 Lucrative Opportunities in the Regenerative Medicines Market

5 Market Overview (Page No. - 31)
    5.1 Introduction
    5.2 Regenerative Medicines Market Segmentation
           5.2.1 Regenerative Medicines Market Segmentation, By Therapy
           5.2.2 Regenerative Medicines Market Segmentation, By Product
           5.2.3 Market Segmentation, By Application
    5.3 Market Dynamics
    5.4 Drivers
           5.4.1 Government and Private Funding to Support the Development of Regenerative Medicines Products
           5.4.2 Increase in Global Healthcare Expenditure
           5.4.3 Increase in Aging Population
    5.5 Restraints
           5.5.1 Stringent Regulatory Approval Process for Regenerative Medicines
           5.5.2 Ethical Issues With the Use of Embryonic Stem Cell for Research and Development
    5.6 Opportunities
           5.6.1 Rising Demand for Organ Transplantation
           5.6.2 Strong Product Pipeline to Drive the Market
           5.6.3 Increase in R&D Spending
    5.7 Challenges
           5.7.1 Lack of Clear Regulatory Guidelines
           5.7.2 High Costs Incurred in Stem Cell Processing

6 Global Regenerative Medicines Market, By Product (Page No. - 40)
    6.1 Introduction
    6.2 Cell-Based Products
           6.2.1 Autologous Cell-Based Products
           6.2.2 Allogeneic Cell-Based Products
    6.3 Acellular Products

7 Global Regenerative Medicines Market, By Therapy (Page No. - 50)
    7.1 Introduction
    7.2 Cell Therapy
    7.3 Gene Therapy
    7.4 Tissue Engineering
    7.5 Immunotherapy

8 Regenerative Medicines Market, By Application (Page No. - 58)
    8.1 Introduction
    8.2 Orthopedic & Musculoskeletal Spine
    8.3 Dermatology
    8.4 Cardiovascular
    8.5 Central Nervous System
    8.6 Oncology
    8.7 Diabetes
    8.8 Others

9 Global Regenerative Medicines Market, By Region (Page No. - 71)
    9.1 Introduction
    9.2 North America
           9.2.1 U.S.
           9.2.2 Canada
    9.3 Europe
           9.3.1 Germany
           9.3.2 UK
           9.3.3 France
           9.3.4 Italy
           9.3.5 Spain
           9.3.6 Rest of Europe (RoE)
    9.4 Asia-Pacific
    9.5 Rest of the World (RoW)

10 Competitive Landscape (Page No. - 126)
     10.1 Overview
     10.2 Market Share Analysis
     10.3 Competitive Situation and Trends
             10.3.1 New Product Launches
             10.3.2 Acquisitions
             10.3.3 Regulatory Approvals
             10.3.4 Partnerships

11 Company Profile (Page No. - 133)
(Overview, Financial*, Products & Services, Strategy, and Developments)
     11.1 Introduction
     11.2 Vertex Pharmaceuticals Incorporated
     11.3 Celgene Corporation
     11.4 Acelity (KCI Licensing)
     11.5 Nuvasive, Inc.
     11.6 Organogenesis Inc.
     11.7 Japan Tissue Engineering Co., Ltd (Subsidiary of Fujifilm Holdings Corporation)
     11.8 Vericel Corporation
     11.9 Cytori Therapeutics Inc.
     11.10 Stemcells, Inc.
     11.11 Advantagene, Inc.
     11.12 Mesoblast Ltd

*Details Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. - 153)
     12.1 Insights From Industry Experts
     12.2 Discussion Guide
     12.3 Introducing RT: Real-Time Market Intelligence
     12.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     12.5 Available Customizations
     12.6 Related Reports


List of Tables (75 Tables)

Table 1 Global Regenerative Medicines Market Size, By Product, 2014–2021 (USD Billion)
Table 2 Cell-Based Market Size, By Type, 2014–2021 (USD Billion)
Table 3 Cell-Based Market Size, By Region, 2014–2021 (USD Billion)
Table 4 Autologous Market Size, By Region, 2014–2021 (USD Billion)
Table 5 Allogeneic Market Size, By Region, 2014–2021 (USD Billion)
Table 6 Acellular Market Size, By Region, 2014–2021 (USD Billion)
Table 7 Global Market, By Therapy, 2014–2021 (USD Billion)
Table 8 Cell Therapy Market, By Region, 2014-2021 (USD Billion)
Table 9 Gene Therapy Market, By Region, 2014-2021 (USD Billion)
Table 10 Tissue Engineering Market, By Region, 2014-2021 (USD Billion)
Table 11 Immunotherapy Market, By Region, 2014-2021 (USD Billion)
Table 12 Market Size, By Application, 2014–2021 (USD Billion)
Table 13 Orthopedic & Musculoskeletal Spine Market, By Region, 2014–2021 (USD Billion)
Table 14 Dermatology Market, By Region, 2014–2021 (USD Billion)
Table 15 Cardiovascular Market, By Region, 2014–2021 (USD Billion)
Table 16 Central Nervous System Market, By Region, 2014–2021 (USD Billion)
Table 17 Oncology Market, By Region, 2014–2021 (USD Billion)
Table 18 Diabetes Market, By Region, 2014–2021 (USD Billion)
Table 19 Others Market, By Region, 2014–2021 (USD Billion)
Table 20 Global Market, By Region, 2014–2021 (USD Billion)
Table 21 North America Market, By Geography, 2014–2021 (USD Billion)
Table 22 North America Market, By Product, 2014–2021 (USD Billion)
Table 23 North America Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 24 North America Market, By Application, 2014–2021 (USD Billion)
Table 25 North America Market, By Therapy, 2014–2021 (USD Billion)
Table 26 U.S. Market, By Product, 2014–2021 (USD Billion)
Table 27 U.S. Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 28 U.S. Market, By Application, 2014–2021 (USD Billion)
Table 29 U.S. Market, By Therapy, 2014–2021 (USD Billion)
Table 30 Canada Market, By Product, 2014–2021 (USD Billion)
Table 31 Canada Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 32 Canada Market, By Application, 2014–2021 (USD Billion)
Table 33 Canada Market, By Therapy, 2014–2021 (USD Billion)
Table 34 Europe Market, By Geography, 2014–2021 (USD Billion)
Table 35 Europe Market, By Product, 2014–2021 (USD Billion)
Table 36 Europe Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 37 Europe Market, By Application, 2014–2021 (USD Billion)
Table 38 Europe Market, By Therapy, 2014–2021 (USD Billion)
Table 39 Germany Market, By Product, 2014–2021 (USD Billion)
Table 40 Germany Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 41 Germany Market, By Application, 2014–2021 (USD Billion)
Table 42 Germany Market, By Therapy, 2014–2021 (USD Billion)
Table 43 UK Market, By Product, 2014–2021 (USD Billion)
Table 44 UK Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 45 UK Market, By Application, 2014–2021 (USD Billion)
Table 46 UK Market, By Therapy, 2014–2021 (USD Billion)
Table 47 France Market, By Product, 2014–2021 (USD Billion)
Table 48 France Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 49 France Market, By Application, 2014–2021 (USD Billion)
Table 50 France Market, By Therapy, 2014–2021 (USD Billion)
Table 51 Italy Market, By Product, 2014–2021 (USD Billion)
Table 52 Italy Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 53 Italy Market, By Application, 2014–2021 (USD Billion)
Table 54 Italy Market, By Therapy, 2014–2021 (USD Billion)
Table 55 Spain Market, By Product, 2014–2021 (USD Billion)
Table 56 Spain Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 57 Spain Market, By Application, 2014–2021 (USD Billion)
Table 58 Spain Market, By Therapy, 2014–2021 (USD Billion)
Table 59 Rest of Europe(RoE) Market, By Product, 2014–2021 (USD Billion)
Table 60 Rest of Europe(RoE) Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 61 Rest of Europe (RoE) Market, By Application, 2014–2021 (USD Billion)
Table 62 Rest of Europe (RoE) Market, By Therapy, 2014–2021 (USD Billion)
Table 63 Asia-Pacific Market, By Product, 2014–2021 (USD Billion)
Table 64 Asia-Pacific Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 65 Asia-Pacific Market, By Application, 2014–2021 (USD Billion)
Table 66 Asia-Pacific Market, By Therapy, 2013–2021 (USD Billion)
Table 67 RoW Market, By Product, 2014–2021 (USD Billion)
Table 68 RoW Cell-Based Products Market, By Type, 2014–2021 (USD Billion)
Table 69 RoW Market, By Application, 2014–2021 (USD Billion)
Table 70 RoW Market, By Therapy, 2014–2021 (USD Billion)
Table 71 New Product Launches, 2013–2016
Table 72 Acquisitions, 2014–2016
Table 73 Regulatory Approvals, 2013–2016
Table 74 Partnerships, 2016
Table 75 Agreements, 2013–2016


List of Figures (91 Figures)

Figure 1 Research Design
Figure 2 Market Size Estimation Methodology: Bottom-Up Approach
Figure 3 Market Size Estimation Methodology: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Market, By Product (2016 vs 2021)
Figure 7 Market, By Therapy, 2016 vs 2021
Figure 8 Orthopedic & Musculoskeletal Spine Form the Largest Application Segment
Figure 9 Global Market to Witness High Growth During the Forecast Period
Figure 10 Cell Therapy Segment Dominates the Market
Figure 11 Asia to Witness the Highest Growth Rate During the Forecast Period
Figure 12 Market Segmentation
Figure 13 Market Segmentation, By Therapy
Figure 14 Market Segmentation, By Product
Figure 15 Market Segmentation, By Application
Figure 16 Drivers, Restraints, Opportunities, and Challenges
Figure 17 Global Market, By Product
Figure 18 Cell-Based Products Segment Accounted for the Largest Share of the Global Market in 2015
Figure 19 Cell-Based Products, By Type
Figure 20 Allogeneic Segment Accounted for the Largest Share of the Cell-Based Regenerative Medicines Market in 2015
Figure 21 North America Estimated to Account for the Largest Share of the Cell-Based Regenerative Medicines Market in 2016
Figure 22 North America Estimated to Account for the Largest Share of the Autologous Regenerative Medicines Market in 2016
Figure 23 North America to Account for the Largest Share of Allogeneic Regenerative Medicines Market in 2016
Figure 24 Asia-Pacific Expected to Be the Fastest-Growing Segment of the Acellular Regenerative Medicines Market During the Forecast Period
Figure 25 Global Market, By Therapy
Figure 26 The Cell Therapy Segment to Lead the Global Market During the Forecast Period
Figure 27 Cell Therapy Market, By Region, 2016 & 2021 (USD Billion)
Figure 28 Gene Therapy Market, By Region, 2016 & 2021 (USD Billion)
Figure 29 Tissue Engineering Market, By Region, 2016 & 2021 (USD Billion)
Figure 30 Immunotherapy Market, By Region, 2016 & 2021 (USD Billion)
Figure 31 Market Segmentation, By Application
Figure 32 Orthopedic & Musculoskeletal Spine Segment Dominated the Regenerative Medicine Application Market in 2015
Figure 33 North America Accounted for the Largest Share of the Global Market for Orthopedic & Musculoskeletal Spine in 2015
Figure 34 North America Dominated the Market for Dermatology in 2015
Figure 35 Asia-Pacific is the Fastest Growing Region in the Global Market for Cardiovascular Applications
Figure 36 North America Dominated the Market for Central Nervous System Applications in 2015
Figure 37 Asia-Pacific is the Fastest Growing Region in the Global Market for Oncology Application
Figure 38 Asia-Pacific is the Fastest Growing Region in the Global Market for Diabetes Application
Figure 39 North America Dominated the Market for Other Applications in 2015
Figure 40 Regional Snapshot (2015)
Figure 41 The Market in the Asia-Pacific Region is Projected to Grow at the Highest CAGR During the Forecast Period
Figure 42 North America Market Snapshot
Figure 43 Cell-Based Products Segment Accounted for the Largest Share of the North America Market in 2015
Figure 44 Orthopedic & Musculoskeletal Spine Application Segment Accounted for the Largest Share of the North America Regenerative Medicines Market in 2015
Figure 45 Cell Therapy Segment Accounted for the Largest Share of the North America Regenerative Medicines Therapy Market in 2015
Figure 46 Cell-Based Products Segment Accounted for the Largest Share of the U.S. Regenerative Medicines Market in 2015
Figure 47 Orthopedic & Musculoskeletal Spine Application Segment Accounted for the Largest Share of the U.S. Regenerative Medicines Market in 2015
Figure 48 Cell Therapy Segment Accounted for the Largest Share of the U.S. Regenerative Medicines Therapy Market
Figure 49 Cell-Based Products Segment Accounted for the Largest Share of the Canada Regenerative Medicines Market in 2015
Figure 50 Orthopedic & Musculoskeletal Spine Application Segment Accounted for the Largest Share of the Canada Regenerative Medicines Market in 2015
Figure 51 Cell Therapy Segment Accounted for the Largest Share of the Canada Regenerative Medicines Therapy Market
Figure 52 Europe Regenerative Medicines Market Snapshot
Figure 53 Among Products, the Cell-Based Products Segment Led the Europe Regenerative Medicines Market in 2015
Figure 54 Among Applications, the Orthopedic & Musculoskeletal Spine Segment Accounted for the Largest Share in the Europe Regenerative Medicines Market in 2015
Figure 55 The Cell Therapy Segment Led the Europe Regenerative Medicines Market in 2015
Figure 56 Cell-Based Products Segment Accounted for the Largest Share of the Germany Regenerative Medicines Market in 2015
Figure 57 Among Applications, the Orthopedic & Musculoskeletal Spine Segment Accounted for the Largest Share in the Germany Regenerative Medicines Market in 2015
Figure 58 The Cell Therapy Segment Led the Germany Regenerative Medicines Market in 2015
Figure 59 Cell-Based Products Segment Accounted for the Largest Share of the U.K. Regenerative Medicines Market in 2015
Figure 60 Among Applications, the Orthopedic & Musculoskeletal Spine Segment Accounted for the Largest Share in the UK Regenerative Medicines Market in 2015
Figure 61 The Cell Therapy Segment Led the UK Regenerative Medicines Market in 2015
Figure 62 Cell-Based Products Segment Accounted for the Largest Share of the France Regenerative Medicines Market in 2015
Figure 63 Among Applications, the Orthopedic & Musculoskeletal Spine Segment Accounted for the Largest Share in the France Regenerative Medicines Market in 2015
Figure 64 The Cell Therapy Segment Led the France Regenerative Medicines Market in 2015
Figure 65 Cell-Based Products Segment Accounted for the Largest Share of the Italy Regenerative Medicines Market in 2015
Figure 66 Among Applications, the Orthopedic & Musculoskeletal Spine Segment Accounted for the Largest Share in the Italy Regenerative Medicines Market in 2015
Figure 67 The Cell Therapy Segment Led the Italy Regenerative Medicines Market in 2015
Figure 68 Cell-Based Products Segment Accounted for the Largest Share of the Spain Regenerative Medicines Market in 2015
Figure 69 Among Applications, the Orthopedic & Musculoskeletal Spine Segment Accounted for the Largest Share in the Spain Regenerative Medicines Market in 2015
Figure 70 The Cell Therapy Segment Led the Spain Regenerative Medicines Market in 2015
Figure 71 Cell-Based Products Segment Accounted for the Largest Share of the Rest of the Europe (RoE) Regenerative Medicines Market in 2015
Figure 72 Among Applications, the Orthopedic & Musculoskeletal Spine Segment Accounted for the Largest Share in the Rest of Europe (RoE) Regenerative Medicines Market in 2015
Figure 73 The Cell Therapy Segment Led the Rest of Europe (RoE) Regenerative Medicines Market in 2015
Figure 74 Asia-Pacific Regenerative Medicines Market Snapshot
Figure 75 Among Products, the Cell-Based Products Segment Accounted for the Largest Share in the Asia-Pacific Regenerative Medicines Market in 2015
Figure 76 Among Applications, the Orthopedic & Musculoskeletal Spine Segment Accounted for the Largest Share in the Asia-Pacific Regenerative Medicines Market in 2015
Figure 77 The Cell Therapy Segment Accounted for the Largest Share in the Asia-Pacific Regenerative Medicines in 2015
Figure 78 The Cell-Based Products Segment Accounted for the Largest Share in the RoW Regenerative Medicines Market in 2015
Figure 79 Among Applications, the Orthopedic & Musculoskeletal Spine Segment Accounted for the Largest Share in the RoW Regenerative Medicines Market in 2015
Figure 80 The Cell Therapy Segment Accounted for the Largest Share in the RoW Regenerative Medicines Market in 2015
Figure 81 Leading Market Players Adopted Both Organic and Inorganic Growth Strategies Over the Last Four Years (2013–2016)
Figure 82 Global Regenerative Medicines Market Share Analysis, By Key Player, 2015
Figure 83 Battle for Market Share: New Product Launches & Product Enhancements is the Key Strategy
Figure 84 Geographic Revenue Snapshot (2015)
Figure 85 Vertex Pharmaceuticals Incorporated: Company Snapshot
Figure 86 Celgene Corporation: Company Snapshot
Figure 87 Acelity (KCI Licensing): Company Snapshot
Figure 88 Nuvasive, Inc.: Company Snapshot
Figure 89 Vericel Corporation: Company Snapshot
Figure 90 Cytori Therapeutics Inc.: Company Snapshot
Figure 91 Stemcells, Inc.: Company Snapshot

The global regenerative medicines market size is expected to reach USD 49.41 Billion by 2021, at a CAGR of 23.7% during the forecast period of 2016 to 2021.

The report on global market analyzes and segments the market on the basis of product, therapy, application, and region. It analyzes the competitive developments, such as alliances, joint ventures, and mergers & acquisitions in the global regenerative medicines market. This market is also analyzed with an explicit focus on the high-growth applications and fastest-growing market segments.

Regenerative medicines replace or regenerate human cells, tissues, or organs, to restore normal function. These medicines repair tissue or organ function lost due to old age, disease, congenital defects, or damage due to trauma, by stimulating previously irreparable organs.

The driving forces for the global market include increasing use of regenerative medicines in cancer research and drug discovery, increasing investments by pharmaceutical companies, government initiatives, and rapid increase in the organ transplantation. The restraints for this market include lack of experienced professionals and budget constraints.

By product, cell-based products segment dominated the regenerative medicines market in 2015 due to large number of organ transplantation surgeries and extensive applications of cell-based products in the treatment of many diseases. Cell-based products are further segmented into allogeneic and autologous-based products.

By therapy, the segments are cell therapy, gene therapy, immunotherapy, and tissue engineering. The cell therapy segment is expected to dominate the market in 2016 owing to the availability of various cell therapy products and investments from the pharmaceutical companies.

By application, the segments are orthopedic & musculoskeletal spine, dermatology, CNS, cardiovascular, oncology, diabetes, and others where orthopedic & musculoskeletal spine segment is estimated to dominate the market in 2016 owing to increasing investments in orthopedic research and increasing number of musculoskeletal cases. According to the U.S. Centers for Medicare and Medicaid Services, approximately 900,000 surgeries requiring bone restructuring or regeneration are performed annually, with the most common being spinal fusion (about 450,000 surgeries performed annually in the U.S.).

The global market was dominated by North America in 2015, followed by Europe, Asia-Pacific, and Rest of the World (RoW). North America is expected to continue to lead the market in coming years, followed by Europe. The market in Asia-Pacific is expected to have the highest CAGR during the forecast period from 2016 to 2021. The growth in this region is expected to be driven by of the increasing research in regenerative medicines especially in Japan, increasing per capita healthcare expenditure, and increasing government initiatives.

Regenerative Medicines Market

Some of the key players in the global regenerative medicines market are Celgene Corporation (U.S.), Acelity (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), among others.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Biotechnology Markets on KnowledgeStore
Request Demo